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Abstract
Introduction: There is a relative lack of information about the death rate and morbidity of non-cystic fibrosis
bronchiectasis and most studies are limited due to referral bias. We wanted to assess death rate and morbidity in
those patients at our hospital.
Methods: Adult patients seen at our department between June 2006 and November 2009 were recruited if the
key string “bronchiect-” was mentioned in electronic clinical records and if chest CT imaging was available. Clinical
records of all patients with confirmed radiologic diagnosis of bronchiectasis were reviewed and clinical
characteristics were analyzed.
Results: 539 patients with a radiographic diagnosis of non-cystic fibrosis bronchiectasis were identified in a
retrospective cross-sectional analysis giving a prevalence of 2.6% in our hospital population. A wide range of
etiologies was found with idiopathic bronchiectasis in 26%. In the 41 months interval, 57 patients (10.6%) died. We
found a median exacerbation rate of 1.94 per year. Bacterial colonization status was associated with more deaths,
exacerbation rate, symptoms and reduced pulmonary function. Pulmonary hypertension was found in 48% of our
patients.
Conclusions: We evaluated a large non-cystic fibrosis bronchiectasis population, and provided new
epidemiological data on associations between clinical characteristics and deaths and morbidity in these patients.
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Introduction
First described by Rene Theophile Laënnec in 1819,
bronchiectasis (BX) are now defined as permanently
dilated airways due to chronic bronchial inflammation
caused by inappropriate clearance of various microorgan-
isms and recurrent or chronic infection [1,2]. Diagnosing
BX has become significantly easier with the advent of
high resolution computed tomography (HRCT), which
has proved to be highly sensitive for demonstrating
bronchiectatic change in the airways [3]. Overall, postin-
fectious and idiopathic BX are the most frequent cause of
non-CF bronchiectasis (NCFB), although the list of
potential etiologies is extensive [4-6].
In the past, several studies evaluated clinical and micro-
biological characteristics of this NCFB population [5-13].
Although these studies identified a number of risk factors
associated with lung function decline, the populations
studied are limited due to referral bias. Most descriptive
studies recruited patients with NCFB who were referred
to their institution with a suspected or established clinical
diagnosis of NCFB. As a result, the populations studied
consist of a large number of patients with rare diseases
and exclude certain subgroups such as smokers and
patients with COPD [9-11]. Due to the heterogeneity of
these study populations, the true burden of NCFB may
be underestimated. There is a relative lack of information
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tion. Such information is important as it allows us to
prioritize treatment options and gain insights for proper
design of clinical trials in NCFB. Our aim was to identify
all patients with a radiologic diagnosis of BX in an unse-
lected manner in order to assess mortality and morbidity
in those patients with NCFB and to identify risk factors
for mortality and morbidity.
Methods
Study population and patient assessment
We performed a search in the electronic patient file data-
base of the University Hospital of Leuven, Belgium. This
database lists patient records of all the patients seen at
the University Hospital Leuven, which serves both as a
local hospital and training center for the region of Leu-
ven/Vlaams-Brabant as well as a national secondary and
tertiary referral center. The search was done using these
criteria: adult patients with the key string “bronchiect-”
mentioned in the clinical records, with a contact at the
department of Respiratory Medicine of our hospital
between June the 1
st 2006 (the furthest date we could go
back in the electronic database) & November the 1
st
2009 and who had CT imaging of the chest available.
Approval was obtained from the local ethical committee
of UZ Leuven, Belgium.
The chest CT scan images of all these patients were re-
assessed to confirm/exclude the presence of BX. CT
scans were performed by one of the UZ Leuven respira-
tory radiologists or at other centers. Images obtained
using 1 mm collimation at full inspiration were reviewed
and BX was deemed to be present if there was one or
more of the following criteria: a bronchoarterial ratio
greater than 1, lack of tapering of the bronchi and visuali-
zation of bronchi within 1 cm of costal or paravertebral
pleura or abutting the mediastinal pleura [14].
In the patients with BX confirmed on chest CT scan,
clinical records were retrospectively reviewed and the fol-
lowing characteristics were noted: age, sex, weight, age at
diagnosis, smoking history, BX diagnostic investigations
that were performed and/or final diagnosis listed, current
respiratory symptoms at diagnosis and outside an exacer-
bation (presence/absence of chronic cough, sternal pain,
wheezing, hemoptysis or shortness of breath; total number
of respiratory symptoms (1 to 5)), the number of exacerba-
tions the first year after CT based diagnosis of BX (defined
as the need for antibiotic treatment due to increased
respiratory symptoms), presence of gastro-esophageal
reflux disease (GERD)(defined as presence of esophagitis
on gastroscopy and/or an abnormal 24 hour pH monitor-
ing), presence of sinusitis (defined as an abnormal sinus
CT scan and/or suggestive symptoms such as postnasal
drip, chronic (purulent) discharge from the nose or symp-
toms of pain or tenderness over one of the sinuses) and
the presence of pulmonary hypertension (PH)(defined as a
systolic pulmonary arterial pressure of ≥36 mmHg on
echocardiography assuming normal right atrial pressure of
5 mmHg) [15]. All sputum culture results obtained during
the study period were reviewed and bacteria found since
the diagnosis of BX were registered even during an exacer-
bation. All patients underwent spirometry according to
ATS criteria [16-18] and the best results at diagnosis and
outside an exacerbation were noted. Follow-up was by the
different outpatient pulmonary clinics and depended on
severity and stage of the underlying etiology and disease
with a minimum of once per year. Standard follow-up at
the NCFB outpatient clinic iso n c ee v e r yt h r e et of o u r
months.
Statistics
Associations between characteristics were analyzed using a
broad set of statistical tests. Logistic, Poisson and linear
regression models were used for binary, count and contin-
uous outcomes respectively. Chi square tests with calcula-
tion of odds ratios (OR) were used for frequency
distributions and non-parametric tests such as Mann-
Whitney U test were chosen when the assumption of nor-
mal distribution was violated. Data were analyzed with
GraphPad Prism4.01 and SAS9.1.3. The p-values reached




The patient selection algorithm is shown in Figure 1 and
Additional file 1: Supplement text S1. Further analysis and
chart review was done in this population of 539 NCFB
patients. Patient characteristics are listed in Table 1.
Patient medical files were reviewed to identify the under-
lying etiology. We did not find a clear underlying cause
for the BX in 170 patients. In 22 of these patients there
were two possible diagnoses and for the subgroup analy-
s i s ,p a t i e n td a t aw e r ei n c l u d e di nb o t hd i a g n o s t i cs u b -
groups. 148 patients lacking a final diagnosis, although
full diagnostic work-up had been performed, were labeled
as having idiopathic NCFB. The underlying etiology of
the BX is shown in Figure 2 and Table 2. Analysis
showed that BX due to thoracic cancer (OR = 3; p =
0.004), COPD (OR = 4; p < 0.0001) and interstitial lung
disease (OR = 2; p = 0.02) were mostly male. Patients
with idiopathic BX were predominantly female (OR = 2;
p < 0.0001).
During the study period, a total of 20,998 patients
were seen at least once in the department of adult
Respiratory Medicine of which 539 had a radiological
diagnosis of NCFB, giving an estimated prevalence of
2.6% amongst the overall patient population seen for
respiratory problems at our hospital.
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There was more sinusitis in NCFB patients with Primary
Ciliary Dyskinesia (PCD) and idiopathic BX and less in
patients with COPD, thoracic cancer and interstitial lung
disease. Patients with sinusitis had more different species
of bacteria present in sputum (p < 0.0001) with signifi-
cance for PA (P = 0.0026; OR = 1.88), encapsulated Pseu-
domonas aeruginosa (PA) (p = 0.0013; OR = 2.35) and
Staphylococcus aureus (SA) (p = 0.0063; OR = 1.85).
Patients with sinusitis had more symptoms than others
(p = 0.0004) with a significant association between sinusi-
tis and cough (p = 0.01; OR = 1.93), wheezing (p = 0.033;
OR = 1.57) and sternal pain (p = 0.0247; OR = 1.65), inde-
pendent of the underlying etiology. Other results on symp-
toms can be seen in Additional file 1: Supplement text S2.
Gastro-esophageal reflux
Signs of GERD were present in 28% of our patients with
NCFB. There was no significant difference in the pre-
sence of GERD between patients with different NCFB
etiologies. The presence of shortness of breath was sig-
nificantly associated with GERD (p = 0.001; OR = 2.4)
and remained significant after correcting for underlying
etiology. Cough, when controlled for etiology was also
significantly associated with GERD (p = 0.0162; OR =
1.98). Overall, the number of symptoms in patients with
GERD was higher than in patients without documented
GERD (p = 0.0051). These patients with GERD also had
more different bacteria present in their sputum cultures
than patients without GERD (p = 0.016). The presence
of SA (p = 0.0007; OR = 2.16) but not PA (p = 0.068;
OR = 1.48) was associated with the presence of GERD.
Bacterial colonization
Sixty patients did not have any record of sputum culture
or bronchoalveolar lavage (BAL) culture during the
study period. The sputum culture results of the other
patients are summarized in Figure 3. The main bacteria
found are PA in 30%, Haemophilus influenzae in 31%,
SA in 23%, Aspergillus fumigatus in 20%, Streptococcus
pneumonia in 20% and Moraxella catharralis in 15% of
the patients. Other bacteria found are listed in Addi-
tional file 1: Supplement text S3.
Underlying etiology was associated with the number of
total different bacteria cultured in sputum. Idiopathic BX
Figure 1 Patient selection algorithm of adult patient files reviewed. CF = Cystic fibrosis; CFLD = CF Like Disease; BX = Bronchiectasis; CT =
Computer Tomography; LTX = Lung transplant patients; non-CF Bx = Non-Cystic Fibrosis Bronchiectasis.
Table 1 Demography and smoking status of the studied
population
Male/Female ratio 299/240 (55.5%/44.5%)
Age (years) median 67; p25-75 57-75
Age at diagnosis (years) median 62; p25-75 51-71
BMI (kg/m²) at diagnosis median 24; p25-75 21-27
Active smoker 69/539 (12.8%)
Ex-smoker 185/539 (34.3%)
Never smoked 268/539 (49.7%)
Passive smoker only 17/539 (3.1%)
FVC (% pred) mean 83% ± 23%
FEV1 (% pred) mean 67% ± 25%
TLC (% pred) mean 92% ± 18%
RV (% pred) mean 116% ± 42%
TLCO (% pred) mean 62% ± 21%
Exacerbations/year 1.94 (median 1; p25-75 1-3; range 0-12)
Middle column shows absolute numbers and percentages are listed in the
brackets. BMI = Body Mass Index; FEV1 = Forced expiratory volume in one
second; FVC = Forced vital capacity; RV = Residual Volume; p = percentile;
pred = predicted; TLC = Total Lung Capacity; TLCO = Transfer Factor of the
Lung for Carbon Monoxide
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and interstitial lung disease with BX (p < 0.0001) had less
o f t e nb a c t e r i ap r e s e n ti ns p u t u mw h i l eb a c t e r i aw e r e
found more often in sputum cultures of patients with
A B P A( p=0 . 0 0 1 ) ,P C D( p=0 . 0 0 1 )a n dC O P D( p<
0.0001). Subanalysis showed that PA, Moraxella catthar-
alis, Streptococcus pneumonia and Escherichia coli were
seen significantly more often in COPD patients and the
former three significantly less in patients with interstitial
lung disease (p = 0.001). As expected, Aspergillus was
present more often in patients with ABPA (p = 0.0003).
Lung function
T h em e a ns p i r o m e t r yv a l u e sa td i a g n o s i sa r es h o w ni n
Table 1. Spirometry results were related to the underlying
etiology (FEV1 p < 0.0001; FVC p = 0.008) with a signifi-
cantly lower FEV1 in COPD patients as compared to the
NCFB patients with other etiologies (p < 0.0001). There
was a significant negative association between FEV1 and
number of respiratory symptoms, with a decrease of 104
ml (p = 0.0063) or 3.7% (p = 0.0012) per symptom. Airway
resistance and residual volume were correlated with total
number of bacteria in sputum, while FEV1 and FVC were
negatively correlated with total number of cultured bac-
teria (all: p < 0.0001). A worse lung function was asso-
ciated with presence of PA (p < 0.0005), Haemophilus
influenzae (p = 0.05), Streptococcus pneumonia (p = 0.05),
SA (p = 0.05), Moraxella catharralis (p = 0.001) and Ste-
notrophomonas maltophilia (p = 0.01).
Pulmonary hypertension
E c h o c a r d i o g r a p h yd a t aw e r ea v a i l a b l ei n2 8 9o ft h e5 3 9
patients (53.6%). In total 140 of the 289 (48.4%) patients
were diagnosed with PH, with information about their
systolic pulmonary arterial pressure in 130 patients
(without the right atrial pressure of 5 mmHg: median
37.5 mmHg; p25-75 33-48). We found that 10% of the
patients with PH died during the study interval of 41
months. There was no significant correlation between
t h ep r e s e n c eo fP Ha n dt h ec o l o n i z a t i o ns t a t u so rt h e
number of exacerbations. There was a difference in pre-
sence of PH between the different etiologies (p = 0.012):
t h e r ew e r em o r eN C F Bp a t i e n t sw i t hP Hi nt h eC O P D
group and less patients with PH in the postinfectious
group. The severity of PH (systolic pulmonary artery
pressure in mmHg) was not significantly different
between different etiologies (p = 0.067). Patients with
PH had worse FEV1 than patients without PH (p =
0.01), with a trend for FVC (p = 0.08). There was a sig-
nificant inverse correlation between the systolic pulmon-
ary artery pressure (mmHg) and FEV1,F V C ,T L C ,R V
Figure 2 Underlying etiology of the studied population. ABPA
= Allergic Bronchopulmonary Aspergillosis; COPD = Chronic
Obstructive Lung Disease; PCD = Primary Ciliary Dyskinesia, NCFB =
Non Cystic Fibrosis bronchiectasis
Table 2 Further definition of the underlying NCFB etiologies
Postinfectious (84) TB (37), MAC (5), Pertussis (3), Invasive Aspergillosis (2), Measles (1), Diphtheria (1), Blastocystes hominis (1), unkown (34)
COPD (64) GOLD II (10), GOLD III (28), GOLD IV (26)
Interstitial lung disease
(57)
EAA (15), IPF/NSIP (27), BOOP (9), drug induced ILD (3), UIP (3)
Rheumatic lung disease RA (29), Sjögren (5), Sclerodermia (4), AS (1), MCTD (1) (40)
Immunodeficiency (29) CVID (1), HIV (1), hyper IgE syndrome (1), other immunoglobulin deficits (14 dysgammaglobulinemia, 1
agammaglobulinemia, 2 hypogamma-globulinemia), Navajo poikiloderma (1), different types of post transplants (5) (3
kidney, 1 liver and 1 heart), non-thoracic Non-Hodgkin lymphoma (2), chronic lymphatic leukemia (1)
Thoracic cancer (38) adenocarcinoma (9), large cell anaplastic carcinoma (1), squamous cell carcinoma (16), small-cell lung carcinoma (3), thoracic
Non-Hodgkin lymphoma (3), carcinoid (1), mesothelioma (2), solitary pulmonary nodule without tissue diagnosis (3)
Other causes (44) sarcoidosis (13), anatomic malformations (6), UC (6), Crohn (3), SJM (3), aspiration/inhalation (3), a1-ATD (2), CS vasculitis (2),
Wegener (2), MK (1), PE (1), WC (1), Microscopic polyangiitis (1)
The number in brackets states the number of patients. AS = Ankylosing Spondylitis, a1-ATD = alfa-1-antitrypsin deficiency, BOOP = Bronchiolitis Obliterans
Organizing Pneumonia, COPD = Chronic Obstructive Lung Disease, CS = Churg-Strauss, CVID = Common Variable Immunodeficiency, EAA = Extrinsic Allergic
Alveolitis, ILD = Interstitial Lung Disease, IPF = Idiopathic Pulmonary Fibrosis, MAC = Mycobacterium avium complex, MCTD = Mixed Connective Tissue Disease,
MK = Mounier-Kuhn Syndrome, NSIP = Nonspecific Interstitial Pneumonia, PE = Pseudoxanthoma Elasticum, RA = Rheumatoid Arthritis, SJM = Swyer-James-
McLeod Syndrome, TB = Tuberculosis, UC = Ulcerative Colitis, UIP = Usual Interstitial Pneumonia, WC = Williams-Campbell syndrome
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remained after correcting for underlying etiology, with
the exception of RV.
Exacerbation rate
Yearly exacerbation rate is listed in Table 1. Factors asso-
ciated with more exacerbations were sinusitis (p < 0.0001),
GERD (p = 0.048), low FEV1 (p = 0.0003; r = -0.15) num-
ber of different bacteria cultured in sputum (p < 0.0001;
r = 0.34), presence of (encapsulated) PA (both p < 0.0001)
and SA (p = 0.0003) in sputum culture. Etiologies asso-
ciated with an increased exacerbation rate were PCD (p <
0.0001), immunodeficiency (p < 0.0001), anatomical mal-
formations (p < 0.0001) and COPD (p = 0.049). Fewer
exacerbations were noted in patients with thoracic cancer
(p = 0.015), interstitial lung disease (p < 0.0001) and sar-
coidosis (p = 0.0003).
Death rate
During the 41-month period, 57 patients died (10.6%)
(Additional file 1: Figure S5). Subgroup analysis showed
lower 41 month deaths in patients with idiopathic or
postinfectious BX (3.4% and 7.1% respectively) with sig-
nificance for idiopathic NCFB (OR = 0.23; p = 0.0008) as
opposed to other etiologies. Patients with thoracic cancer
and COPD had the highest deaths (30% and 26% respec-
tively; OR = 4.32 and 3.93; both p < 0.0001). More deaths
were also seen in active smokers (OR = 1.98; p = 0.05)
and in former smokers (OR = 1.87; p = 0.045). Death was
associated with number of different bacteria in sputum
cultures, with more deaths when more different species
were present (p = 0.002). Only Escherichia coli (p =
0.0003) and Aspergillus species (p = 0.034) showed signifi-
cant association with death but trends were seen for PA
(p = 0.077), Haemophilus influenzae (p = 0.11), SA (p =
0.11) and Moraxella catharralis (p = 0.056). The number
of symptoms was not associated with death and neither
was the number of exacerbations. Low FEV1 and FVC
(p = 0.0008 & p = 0.002, respectively) and presence of
PH (p = 0.01) were associated with more deaths.
Discussion
Radiological diagnosis NCFB was confirmed in a total of
539 patient which results in a NCFB prevalence of 2.6%
in the patient population of the department of respira-
tory medicine at the University Hospital of Leuven,
Belgium. The use of the electronic medical records data-
base of our hospital to capture potential patients and
thorough review of CT scan and clinical data allowed us
to identify NCFB patients in an unselected manner. We
are confident that we have obtained a nearly full esti-
mate of patients with NCFB at our hospital, which
explains the larger number of patients than similar stu-
dies reported in the literature. The setting of our study
does not allow us to give an exact population estimate
of NCFB, which has been estimated to be much lower
Figure 3 Percentage of bacteria present in sputum or bronchoalveolar lavage culture of NCFB patients. Only bacteria with a prevalence
of more than 5% are shown
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all US population to 1 per 625 Auckland Pacific Island
children [19-21]. Even incidence estimates fall within
this range, running from 3.7 to 17.2 per 100 000 per
year [22-24].
Our database included almost all possible underlying
etiologies in BX [4]. Our population included similar
numbers of idiopathic BX as reported in other cohort
studies but for other etiologies, the number of patients
differed somewhat [5-13]. This discrepancy may be due
to the fact that patients with NCFB were recruited on
the basis of radiological evidence of BX and not only on
the basis that they were referred to our hospital because
of NCFB. As a result, patients with NCFB due to
COPD, ILD or thoracic cancer were also recruited. Gen-
der distribution in our study population showed a small
male predominance, which is due to the inclusion of
patients with NCFB due to COPD, thoracic cancer and
ILD. Previous studies suggested that chronic airway
infection due to NCFB was a more common and more
virulent disease in women [5-11,13,25]. In our study
population, patients with idiopathic BX were predomi-
nantly female.
Our 41 month death rate of 10.6% is in line with the
findings of Loebinger et al. who found survival rates of
91% at 4 years [26]. We found a lower death rate in idio-
pathic BX, indicating that a lack of underlying etiology of
NCFB bears a favorable prognosis. One possible explana-
tion for this marked difference could be the absence of
comorbidities in patients with idiopathic NCFB as com-
pared to etiologies such as COPD and rheumatic disease.
Another possible explanation might be that patients with
idiopathic BX have a less severe pathophysiological
vicious cycle of impaired mucociliary clearance, infection
and inflammation and as a result develop lung damage
more gradually than other known etiologies. In a study
by Reiff et al., patients with idiopathic BX were shown to
have less extensive disease on CT images than other
etiologies, which is in agreement with our findings [27].
King et al. found that patients with idiopathic BX had a
low neutrophil oxidative burst, which may result in less
severe airway inflammation [28]. Children with idiopathic
BX had less viscous sputum than children with CF or
chronic bronchitis, which may lead to improved cough
transportability of sputum [29]. Additional research is
needed to unravel the pathogenesis of idiopathic BX. Our
finding of a high presence of sinusitis in this subgroup
suggests an upper airways dysfunction.
In our study population, we observed an exacerbation
rate of nearly 2 exacerbations per year, indicative of a sig-
nificant burden of disease in patients with NCFB. This
exacerbation rate was slightly higher than previously
reported by O’Donnell et al. (1.5 exacerbations per year in
patients with idiopathic BX) [30]. The higher exacerbation
rate is probably due to the inclusion of other etiological
groups such as COPD, where recent research has shown a
difference in oxidative stress in the lungs of COPD
patients versus BX patients. Tzortzaki et al. showed a
higher specific sputum marker of oxidant-induced DNA
damage in COPD patients versus BX patients [31].
Another reason for differences in reported exacerbation
rate might be the criteria we used to define exacerbation,
given the lack of a clear definition of a NCFB exacerbation.
In the current study, an exacerbation was defined not
merely on the basis of symptoms, clinical or radiologic
changes but on the need for a therapeutic intervention
with antibiotics (oral or IV). Interstitial lung disease, sar-
coidosis and thoracic cancer showed a lower exacerbation
rate. These patients also had a lower number of symptoms
and lower number of different bacteria in sputa, explaining
their lower exacerbation rate. They could be regarded as
having ‘dry’ bronchiectasis, a term previously used to
describe patients with BX but without expectoration of a
lot of sputa [32].
Our data showed a significant negative correlation
between FEV1 and exacerbation rate and the FEV1 was
on an average 104 ml or 3.7% lower per symptom
reported by our patients. This is in line with Wilson et
al. who found that lung function correlated with St.-
George’s Respiratory Questionnaire (SGRQ) [33].
In our population of NCFB patients 48% of the patients
with an echocardiographic evaluation had evidence of PH
and the presence of PH was associated with more severe
lung disease (decrease in lung function parameters).
These data are in agreement with similar study data that
showed that PH was present in one out of three patients
with NCFB and correlated with radiographic stage [34].
Alzeer et al. saw that right ventricular dysfunction and
right ventricular dimensions were greater in cystic BX
and were positively correlated with systolic pulmonary
artery pressure and negatively correlated with partial
pressure of oxygen in arterial blood. In more severe BX
disease, there is an impaired perfusion with more capil-
lary bed destruction and left-to-right shunt, leading to
impaired cardiac function and pulmonary gas exchange
[34]. This might explain the bad prognostic factor of PH
in NCFB. Due to the high prevalence of PH, cardiac
assessment with echocardiography is indicated in patients
with NCFB and more severe lung disease. There was no
association between PH and other clinical characteristics.
Despite these findings, PH in BX did not have a signifi-
cant impact on death in our population.
The main advantage of our study is the large patient
sample and the unbiased recruitment with as main inclu-
sion criterion the radiological documentation of BX. Not
only those patients who were referred to our center for
management of their NCFB were recruited but also
patients with other underlying diseases, in whom the
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ing or complicating factor. The main limitation of this
study is its retrospective design. All clinical data were col-
lected by reviewing patient medical records, leaving error
for underreporting. Despite these disadvantages, data are
in line with previous studies. Previous reports suggest that
a triad of mucus plugging in the airways, infection and
inflammation may reinforce each other, lead to progressive
lung damage and result in mortality and morbidity [23]. It
is clear that BX remains a significant health problem,
requiring further research [35]. Our study revealed some
additional factors influencing death and morbidity and
may help to further clarify the different elements that are
important in NCFB (Additional file 1: Table S6 [36]). The
association between the bacterial colonization status and
several clinical outcome parameters suggest the potential
importance of anti-infective treatment. Dhar et al.
reported their experiences with nebulised colistin in a
small cohort of patients with NCFB infected with PA.R e g -
ular colistin reduced the exacerbation and hospitalization
rate, a finding which needs confirmation in larger con-
trolled trials [37].
Conclusion
In summary, NCFB was confirmed radiologically in nearly
3% of the patients seen at the department of respiratory
medicine of our hospital with a wide spectrum of underly-
ing etiologies. Although the general death rate of our
NCFB population is comparable to literature data, we
found that idiopathic BX showed lower death rate, empha-
sizing that a full work-up for NCFB may have prognostic
implications. Repetitive bacterial follow-up with sputum
culture is necessary as presence of PA was high and cul-
ture results were correlated with other factors such as
symptoms, lung function, exacerbation rate and death
rate. Presence of sinusitis and GERD was also associated
with an increased exacerbation rate. Our analysis showed
PH in 48% of the patients, underlining the need for echo-
cardiographic evaluation in patients with BX.
Additional material
Additional file 1: Supplementary data text S1 shows patient
selection algorithm; text S2 describes extra data on symptoms; text
S3 gives additional information on bacteria found; table S4 shows
correlation between lung function and severity of pulmonary
hypertension; figure S5 shows deaths in non-cystic fibrosis
bronchiectasis; table S6 indicates the associations between the
different morbidity factors.
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